Molnupiravir | CAS 2349386-89-4 | USP/EP-Certified Antiviral API for COVID-19 Treatment
Google Keywords: Molnupiravir bulk supplier, antiviral API for COVID-19, USP/EP-certified Molnupiravir, RNA mutagen drug
🌟 Product Overview
Molnupiravir (CAS 2349386-89-4) is an oral antiviral nucleoside analog designed to treat mild-to-moderate COVID-19 by inducing RNA mutagenesis during viral replication, effectively reducing viral load and transmission risk. As a broad-spectrum antiviral agent, it is formulated as a white crystalline powder for clinical use and research applications.
✔️ Key Advantages
High Purity: ≥99% HPLC purity compliant with USP/EP standards, ensuring pharmaceutical-grade quality.
Bulk Customization: Available in 1kg–25kg batches with batch-specific COA, MSDS, and stability data.
Solubility: Optimized for DMSO solubility (≥20 mg/mL) to support preclinical and clinical studies.
🏥 Applications
COVID-19 Therapy: First-line oral treatment to reduce symptom severity and hospitalization rates.
Antiviral Drug Development: Key reference standard for RNA virus-targeted drug discovery.
Research: Mechanistic studies on viral mutagenesis and resistance profiling.
📜 Quality Compliance
Certified under USP/EP guidelines with heavy metals <20 ppm and residual solvents <10 ppm.
Stability tested for 24 months when stored at -20°C in airtight, light-protected packaging.
📈 Market Trends
The global antiviral drug market is projected to grow at 7.8% CAGR (2025-2030), driven by ongoing demand for COVID-19 therapeutics. Molnupiravir’s oral bioavailability and rapid action position it as a critical tool in pandemic preparedness.
China
